Literature DB >> 21353595

Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy.

Chrysanthos Symeonidis1, Eleni Papakonstantinou, Sofia Androudi, Tryfon Rotsos, Eudoxia Diza, Periklis Brazitikos, George Karakiulakis, Stavros A Dimitrakos.   

Abstract

PURPOSE: To investigate the levels of IL-6 in the vitreous of patients with RRD complicated with PVR and correlate the IL-6 levels with matrix metalloproteinase (MMP)-1,-2,-3,-8,-9 and tissue inhibitor of metalloproteinases (TIMP)-1 with respect to RRD extent, duration and PVR grade.
DESIGN: Cohort study. PARTICIPANTS: Twenty-eight vitreous samples from 28 eyes of 28 patients with RRD complicated with PVR.
METHODS: Institutional study. Twenty-eight vitreous samples from 28 eyes of 28 patients with RRD complicated with PVR were collected during pars plana vitrectomy (PPV) and were compared to vitreous control samples. IL-6, MMP-1,-3,-8 and TIMP-1 levels were measured using ELISA while enzymatic activity of MMP-2, and -9 was determined employing gelatin zymography.
RESULTS: Protein IL-6 (p=0.030), MMP-1 (p=0.003), MMP-3 (p=0.003), TIMP-1 (p=0.001) levels as well as enzymatic activity of proMMP-9 (p=0.013), MMP-9 (p=0.017) and proMMP-2 (p=0.010), were significantly increased in PVR patients as compared to controls. IL-6 levels correlated with MMP-1 (p=0.002), proMMP-2 (p=0.006), MMP-3 (p=0.001) and TIMP-1 (p=0.006). Regression analysis revealed positive correlations between IL-6 and all MMPs and TIMP-1.
CONCLUSIONS: Taking into account the previously established effect of interleukins in MMP activity, the findings of this study suggest a role of IL-6 in MMP stimulation during PVR development.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21353595     DOI: 10.1016/j.cyto.2011.02.001

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 expression in murine experimental retinal detachment.

Authors:  Bongsu Kim; Mohamed H Abdel-Rahman; Tiffany Wang; Severin Pouly; Ashraf M Mahmoud; Colleen M Cebulla
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-03       Impact factor: 4.799

2.  Chemokine CXCL-1: activity in the vitreous during proliferative vitreoretinopathy.

Authors:  C Symeonidis; S Androudi; I Georgalas; A Tzamalis; N Chalvatzis; T Rotsos; E Souliou; E Diza; S A Dimitrakos
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330

Review 3.  Diabetic Retinopathy: Vascular and Inflammatory Disease.

Authors:  F Semeraro; A Cancarini; R dell'Omo; S Rezzola; M R Romano; C Costagliola
Journal:  J Diabetes Res       Date:  2015-06-07       Impact factor: 4.011

4.  Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy.

Authors:  V V Chernykh; E V Varvarinsky; E V Smirnov; D V Chernykh; Alexander N Trunov
Journal:  Indian J Ophthalmol       Date:  2015-01       Impact factor: 1.848

Review 5.  Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD).

Authors:  Luis García-Onrubia; Fco Javier Valentín-Bravo; Rosa M Coco-Martin; Rogelio González-Sarmiento; J Carlos Pastor; Ricardo Usategui-Martín; Salvador Pastor-Idoate
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

6.  Doxycycline Ameliorates the Severity of Experimental Proliferative Vitreoretinopathy in Mice.

Authors:  Shun-Hua Chen; Yu-Jheng Lin; Li-Chiu Wang; Hsien-Yang Tsai; Chang-Hao Yang; Yu-Ti Teng; Sheng-Min Hsu
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 7.  Inflammatory and Fibrogenic Factors in Proliferative Vitreoretinopathy Development.

Authors:  Rishika Chaudhary; Robert A H Scott; Graham Wallace; Martin Berry; Ann Logan; Richard J Blanch
Journal:  Transl Vis Sci Technol       Date:  2020-02-21       Impact factor: 3.283

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.